BBIO earnings analysis
What we found in BBIO's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
BridgeBio delivered strong Q2 revenue of $243.7 million, up approximately 25% sequentially and 119% year over year, with $222.4 million from Attruby. Losses improved year over year and liquidity totaled $720.2 million, but EPS of negative $0.78 missed consensus and the company continues to carry substantial debt, royalty obligations and operating losses. The outlook is balanced: management expects liquidity plus Attruby proceeds to fund operations for at least 12 months, while potential royalty increases, pricing reforms, convertible-note exposure and dilution remain material risks.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Attruby drives strong revenue growth
- Revenue increased to $243.7 million from $195 million in the prior quarter and $111 million in the prior-year quarter, representing approximately 25% sequential growth and 119% year-over-year growth. Attruby contributed $222.4 million of product revenue.
- EPS improved year over year
- Reported EPS was negative $0.78, improving from negative $0.84 in Q1 2026 and negative $0.95 in Q2 2025, although it missed the $0.59 consensus loss estimate by $0.19.
- Net loss narrowed
- Net loss narrowed to $155.9 million from $183.8 million in the year-ago quarter; the six-month net loss was $322.4 million versus $353.4 million in the prior-year period.
- Liquidity supports near-term operations
- Liquidity was $720.2 million in cash, cash equivalents and marketable securities, with working capital of $202.5 million. Management expects these resources plus Attruby proceeds to fund operations through at least the next 12 months.
- Secondary supply source added
- The company has taken delivery of commercial Attruby and Beyonttra drug product from a secondary supplier and expects the tablets to enter finished-goods inventory later in 2026 after packaging.
- No reported control deficiencies
- Management reported effective disclosure controls as of June 30, 2026, and stated that no change in internal control over financial reporting materially affected, or was reasonably likely to materially affect, controls during the quarter.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Heavy debt and royalty obligations
- Total consolidated indebtedness was $2.5 billion, including $550.0 million of 2027 Notes, $747.5 million of 2029 Notes, $575.0 million of 2031 Notes and $632.5 million of 2033 Notes. Deferred royalty obligations were an additional $908.7 million.
- Attruby royalty burden may rise
- The Funding Agreement currently requires royalty interest payments equal to 5% of global Attruby net sales, with the rate potentially increasing to a maximum of 10% in 2027. The agreement has a $950.0 million payment cap.
- Convertible notes may pressure liquidity
- The 2027 and 2031 Notes became convertible for a limited period beginning July 1, 2026 and remain convertible through September 30, 2026, potentially requiring cash settlement and reducing liquidity.
- Repurchases compete with cash needs
- The company approved a stock repurchase program of up to $500.0 million but had repurchased 1,904,001 shares for $127.4 million through June 30, 2026, leaving $372.5 million available. Capital deployment could compete with funding needs given the $322.4 million six-month net loss.
- New preferred stock creates dilution
- A new Series A preferred stock issuance comprised 933,900 shares that are initially convertible into 6,777,704 common shares. Conversion could dilute common shareholders, and the preferred stock ranks senior to common stock for dividends and liquidation.
- Pricing reform threatens Attruby economics
- The filing highlights heightened drug-pricing uncertainty: proposed GLOBE and GUARD models could impose additional Medicare rebates, with proposed testing periods beginning October 1, 2026 and January 1, 2027. Attruby's U.S. list price increased from $18,759.12 to $19,790.00 for a 28-day supply in January 2026.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.78
- Segment
- Attruby product revenue: $222.4 million
- Segment
- Other revenue, including royalties and collaboration-related revenue: approximately $21.3 million
What they said about what is next.
No numeric revenue or EPS guidance was provided in the 10-Q. Management stated that cash, cash equivalents, marketable securities and Attruby proceeds are expected to fund operations through at least the next 12 months from filing.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 7, 2026
- BridgeBio reported Q1 2026 revenues of $194.5 million, which beat estimates of $178.8 million, and net product revenue from Attruby increased significantly to $180.6 million. However, the company reported a diluted EPS…
- 10-K · February 24, 2026
- BridgeBio’s 10‑K describes a transition to a commercial-stage portfolio anchored by Attruby (acoramidis), which generated $362.4 million in U.S. net product revenues in 2025 and drove stronger quarterly company revenue…
- 10-Q · August 5, 2025
- BridgeBio reported Q2 revenue of $110.565M (three months ended June 30, 2025) driven by first product sales (net product revenue $71.501M) and higher license/services revenue ($37.440M), materially above Q2 2024 revenue…
- 10-Q · November 12, 2024
- BridgeBio reported Q3 revenue of $2,732,000 and a GAAP net loss attributable to common stockholders of $162,040,000 (net loss per share -$0.86). Revenue declined vs. year-ago ($4,091,000) but improved versus Q2 2024…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing BBIO makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever